Navigation Links
New Data Demonstrates Abbott's Investigational MitraClip(R) System Has Potential to be a Valuable Treatment Option for Patients With Mitral Regurgitation, the Most Common Heart Valve Condition
Date:3/14/2010

unction. Left ventricular diastolic volumes decreased a significant 13 percent (p<0.0001) and left ventricular diastolic dimensions decreased a significant 6.4 percent (p<0.0001) compared to baseline.
  • An improvement in symptoms, with 97.5 percent of patients exhibiting no symptoms (NYHA Functional Class I) or mild symptoms (NYHA Functional Class II) [p<0.0001], whereas at baseline, 52.6 percent of patients had moderate symptoms (NYHA Functional Class III) or severe symptoms (NYHA Functional Class IV). Patients who are classified as NYHA Functional Class III or IV experience marked or severe limitations in physical activity.
  • Meaningful improvements in both physical and mental quality of life compared to baseline as measured by the SF-36 Survey (increase of 4.7 points in the physical quality of life score [p<0.0001] and increase of 5.8 points in the mental quality of life score [p<0.0001]).

  • "The EVEREST II safety and effectiveness results support the MitraClip device as a treatment choice, and show that MitraClip patients still have the option for successful mitral valve surgery afterward if needed," said Donald Glower, M.D., professor of surgery, Cardiovascular and Thoracic Surgery Division, Duke University School of Medicine, Durham, NC; and co-principal investigator of the EVEREST II trial. "The improvements in symptoms, quality of life and cardiac function shown in the EVEREST II trial suggest the MitraClip procedure may be another valuable treatment option for certain patients with significant MR."


    '/>"/>
    SOURCE Abbott
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. New Study Demonstrates Safety of Balloon Sinuplasty(TM) Technology in Pediatric Patients Suffering From Chronic Sinusitis
    2. Tobiras Next-Generation Once-Daily CCR5 Receptor Antagonist Demonstrates Efficacy, Safety and Tolerability in Treatment-Experienced Patients With HIV
    3. Transgenomic Demonstrates Very High Sensitivity Detection of Tumor-Associated KRAS Mutations in Matched Plasma Samples Using COLD-PCR
    4. AsepticSure(TM) Hospital Sterilization System Demonstrates Total Eradication of Super Bugs
    5. Phase 2 Trial of LX4211 Demonstrates Significant and Rapid Improvements in Multiple Parameters in Type 2 Diabetic Patients
    6. Study Demonstrates Value of HPV Screening to Prevent Invasive Cervical Cancer
    7. ERT Demonstrates Patient Safety Expertise in Clinical Trials with New Knowledge Series of Papers
    8. ANA598 Demonstrates Positive 4-Week Results at 200 mg BID
    9. Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies
    10. Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection
    11. European Lung Cancer Screening Trial Demonstrates New Inexpensive Strategy for Improving Accuracy of Diagnosis
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/31/2014)... , October 30, 2014 ... has announced the addition of the  "Process Validation ... to their offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... Science and Risk Based Approach to Process Validation ... Risk Management FDA Process Validation Guidance ...
    (Date:10/31/2014)... -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) announces ... Pharmaceuticals, Third Quarter 2014 Financial Results and Highlights Conference ... ET / 8:30 a.m. PTWhere: , www.isispharm.com ... onto our website listed above. If you are unable ... the webcast will be available for a limited time ...
    (Date:10/31/2014)...  AbbVie (NYSE: ABBV ) today ... Sept. 30, 2014. "Our third-quarter ... with double-digit growth from HUMIRA and several other ... percent in the quarter excluding lipids," said Richard ...  "We exceeded our outlook for the quarter and ...
    Breaking Medicine Technology:Process Validation in the US and EU (Workshop, London) 2Process Validation in the US and EU (Workshop, London) 3Process Validation in the US and EU (Workshop, London) 4Webcast Alert: Isis Pharmaceuticals' Third Quarter 2014 Financial Results Conference Call 2Webcast Alert: Isis Pharmaceuticals' Third Quarter 2014 Financial Results Conference Call 3AbbVie Reports Third-Quarter 2014 Financial Results 2AbbVie Reports Third-Quarter 2014 Financial Results 3AbbVie Reports Third-Quarter 2014 Financial Results 4AbbVie Reports Third-Quarter 2014 Financial Results 5AbbVie Reports Third-Quarter 2014 Financial Results 6AbbVie Reports Third-Quarter 2014 Financial Results 7AbbVie Reports Third-Quarter 2014 Financial Results 8AbbVie Reports Third-Quarter 2014 Financial Results 9AbbVie Reports Third-Quarter 2014 Financial Results 10AbbVie Reports Third-Quarter 2014 Financial Results 11AbbVie Reports Third-Quarter 2014 Financial Results 12AbbVie Reports Third-Quarter 2014 Financial Results 13AbbVie Reports Third-Quarter 2014 Financial Results 14AbbVie Reports Third-Quarter 2014 Financial Results 15AbbVie Reports Third-Quarter 2014 Financial Results 16AbbVie Reports Third-Quarter 2014 Financial Results 17AbbVie Reports Third-Quarter 2014 Financial Results 18AbbVie Reports Third-Quarter 2014 Financial Results 19AbbVie Reports Third-Quarter 2014 Financial Results 20AbbVie Reports Third-Quarter 2014 Financial Results 21AbbVie Reports Third-Quarter 2014 Financial Results 22AbbVie Reports Third-Quarter 2014 Financial Results 23AbbVie Reports Third-Quarter 2014 Financial Results 24
    ... many, clinical studies are few, NEW YORK, ... revealed that a limited amount of clinical research ... anti-aging,products. The study is published in the July/August ... peer-reviewed journal of the,American Society for Aesthetic Plastic ...
    ... (Amex: IMM ) commented today on a ... group of researchers at the National Cancer Institute,on ... enzyme involved in the DNA,repair process (see Note ... proprietary, orally bioavailable prodrug, pafuramidine. Of,interest is furamidine,s ...
    Cached Medicine Technology:OTC Anti-Aging Products: Hype or Hope? 2Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms 2Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms 3
    (Date:10/31/2014)... Oct. 30, 2014 (HealthDay News) -- A comparison of ... surgery found that laparoscopic gastric bypass helped patients shed ... a higher risk of short-term complications and long-term hospitalizations. ... the small intestine, so your body does not absorb ... the National Institutes of Health. Gastric banding is a ...
    (Date:10/31/2014)... HealthDay Reporter THURSDAY, Oct. 30, ... the risk of broken bones and injured joints, a new study ... among 7 percent of people who had an eczema flare-up in ... and 0.6 percent had an injury that caused a limitation of ... skin condition had more than double the risk of having had ...
    (Date:10/30/2014)... could one day provide new treatments for injuries and ... ligaments. , Cartilage, for example, is a hard material ... to work smoothly. UC Davis biomedical engineers, exploring ways ... strong outside the body, report new developments this week ... of Sciences . , "The problem with engineered tissue ...
    (Date:10/30/2014)... by NIH grantees predicts that women must take the ... vaginal sex, whereas just two doses per week can ... finding helps explain why two large clinical trials testing ... show efficacy. Participants in the VOICE and ... antiretroviral) for HIV prevention were counseled to take one ...
    (Date:10/30/2014)... NC (PRWEB) October 30, 2014 Don ... commercial, and health insurance plans for North Carolina residents, ... satellite office in Burlington’s Holly Hill Mall. The new ... with agents already helping customers through all facets of ... purchase. , Allred Insurance spokesman Scott Allred couldn’t be ...
    Breaking Medicine News(10 mins):Health News:Study Compares 2 Common Weight-Loss Surgeries 2Health News:Study Compares 2 Common Weight-Loss Surgeries 3Health News:Eczema Tied to Bone Fracture Risk in Study 2Health News:Making lab-grown tissues stronger 2Health News:Model by NIH grantees explains why HIV prevention dosing differs by sex 2Health News:Allred Insurance Satellite Office Grand Opening 2
    ... Demonstrate Deepening Relationship , Between Edwards and Primary Sponsor ... off its first year as primary sponsor of Carl ... big way with the launch of its latest television ... to air during the national broadcast of the Feb. ...
    ... Prevent Preterm BirthWHITE PLAINS, N.Y., Feb. 11 ... may cause preterm labor in some women, investigate ... contractions and an early birth, and look at ... environmental risk factors for prematurity.The work of seven ...
    ... and St George,s, University of London measured recent exposure to ... British Regional Heart Study by measuring the levels of cotinine ... time points 20 years apart. A blood cotinine level above ... of a heart attack (2), and other studies have suggested ...
    ... Results of a recent study conducted by researchers ... show that cognitive functioning abilities drop as average blood ... , The study appears in this month,s issue of ... Diabetes (MIND) study, a sub-study of the Action to ...
    ... French . , Montreal, February 11th, 2009 ... the nutrients the tumours receive through the blood. The team ... McGill University Health Centre (MUHC) at the Montreal Children,s Hospital, ... a new mechanism that tumours use to stimulate the growth ...
    ... world,s first phase one FDA-approved clinical trial using adult ... conducted by a team of University of Louisville ... with advanced heart disease who already are undergoing bypass ... trial, which uses adult stem cells taken from the ...
    Cached Medicine News:Health News:New Ads Provide Glimpse Into Unique Friendship Between Aflac Duck and Carl Edwards 2Health News:New Ads Provide Glimpse Into Unique Friendship Between Aflac Duck and Carl Edwards 3Health News:New Ads Provide Glimpse Into Unique Friendship Between Aflac Duck and Carl Edwards 4Health News:March of Dimes Provides $2.7 Million in New Funding For Preterm Birth Research 2Health News:March of Dimes Provides $2.7 Million in New Funding For Preterm Birth Research 3Health News:Smokers putting their loved ones at risk of heart attacks 2Health News:Higher blood sugar levels linked to lower brain function in diabetics, study shows 2Health News:Innovative method to starve tumors 2Health News:World's First Cardiac Adult Stem Cell Trial to Take Place in Louisville 2
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    Medicine Products: